| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 50.88 -3.42 (-6.3%) | 10-22 16:01 | ||
| Open: | 51.25 | Pre. Close: | 54.3 |
| High: | 51.9 | Low: | 50.51 |
| Volume: | 24,632,340 | Market Cap: | 83030M |
| Price Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 52.011 - 52.323 | 52.323 - 52.555 |
| Low: | 49.768 - 50.18 | 50.18 - 50.486 |
| Close: | 50.329 - 50.937 | 50.937 - 51.389 |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 68.51  One year: 74.39 |
| Support: | Support1: 50.51 Support2: 42.02 |
| Resistance: | Resistance1: 58.66 Resistance2: 63.69 |
| Pivot: | 59.17 |
| Moving Averages: | MA(5): 55.58 MA(20): 59.86 MA(100): 58.17 MA(250): 59.66 |
| MACD: | MACD(12,26): -1.76 Signal(12,26,9): -0.73 |
| %K %D: | %K(14,3): 2.11 %D(3): 10.43 |
| RSI: | RSI(14): 19.46 |
| 52-Week: | High: 70.05 Low: 49.96 Change(%): -20.1 |
| Average Vol(K): | 3-Month: 615424 10-Days: 1111370 |
| Price, MAs and Bollinger Bands |
|---|
| Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.BMY has closed below the lower band by 8.1%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 349.8% wider than normal. The large width of the bands suggest high volatility as compared to BMY's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
2018-10-22T09:41:53-04:00 AVEO down 4% on mid-stage tivozanib data in kidney cancer 2018-10-22T08:39:13-04:00 Bristol-Myers Squibb down 3% premarket on diminished prospects of overtaking Merck in first-line lung cancer 2018-10-22T08:14:09-04:00 Mirati down 29% premarket on disappointing mid-stage sitravatinib data 2018-10-22T06:45:00-04:00 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 2018-10-22T03:20:00-04:00 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma 2018-10-22T03:15:00-04:00 Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer |
| Financial Analysis | |
|---|---|
| Growth |  |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. | |
| Profitability | |
| Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs. | |
| Solvency | |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. | |
| Efficiency |  |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. | |
| Stock Basics & Statistics | |
|---|---|
| Sector: Healthcare | |
| Industry: Drug Manufacturers - Major | |
| Shares Out. (M) | 1631.88 |
| Shares Float (M) | 1625.64 |
| % Held by Insiders | 0.40 |
| % Held by Institutions | 75.60 |
| Shares Short (K) | 13501 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | 3.380 |
| EPS Est. Current Year | 3.000 |
| EPS Est. Next Year | 3.230 |
| EPS Est. Next Quarter | 0.790 |
| Forward EPS | 3.720 |
| Book Value (p.s.) | 7.420 |
| PEG Ratio | 1.39 |
| Profit Margin | -2.92 |
| Operating Margin | 26.12 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 2.8 |
| Qtrly Rev. Growth | 10.9 |
| Gross Profit (p.s.) | 4.570 |
| Sales Per Share | |
| EBITDA (p.s.) | 1.449 |
| Qtrly Earnings Growth | -59.30 |
| Operating Cash Flow (M) | 5060.00 |
| Levered Free Cash Flow (M) | 3460.00 |
| Stock Valuation | |
|---|---|
| P/E | 15.05 |
| P/E Growth Ratio | -0.06 |
| P/BV | 6.86 |
| P/S | 6276919296.00 |
| P/CF | 16.41 |
| Dividend Yield | 0.06 |
| Dividends & Splits | |
|---|---|
| Dividend | 2.947 |
| Dividend Pay Date | 2018-11-01 |
| Ex-Dividend Date | 2018-10-04 |
| Forward Dividend | 1.600 |
| Last Split Date | |
| Last Split Ratio | -1e+010 |
